Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 6
2018 5
2019 7
2020 6
2021 13
2022 17
2023 13
2024 15
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccination.
Valk AM, Keijser JBD, van Dam KPJ, Stalman EW, Wieske L, Steenhuis M, Kummer LYL, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Horváth B, Hijnen DJ, Schreurs CRG, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Keijzer S, Derksen NIL, van Deelen M, van Mierlo G, Kuijpers TW, Eftimov F, van Ham SM, Ten Brinke A, Rispens T; T2B! Immunity against SARS‐CoV‐2 study group. Valk AM, et al. Among authors: van kempen zle. Allergy. 2024 Jul;79(7):1952-1961. doi: 10.1111/all.16089. Epub 2024 Mar 4. Allergy. 2024. PMID: 38439527
Clinical and humoral response after SARS-CoV-2 breakthrough infection in patients receiving immunosuppressant therapy.
Stalman EW, Wieske L, Keijser JBD, van Dam KPJ, Kummer LYL, Wilbrink MF, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Onno Teng YK, van Paassen P, Busch MH, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Cristianawati O, Brinke AT, Verstegen NJM, Zwinderman KAH, van Ham SM, Rispens T, Welkers MR, Jonges M, Eftimov F, Kuijpers TW; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Among authors: van kempen zle. J Allergy Clin Immunol. 2024 Sep;154(3):754-766.e7. doi: 10.1016/j.jaci.2024.04.031. Epub 2024 May 17. J Allergy Clin Immunol. 2024. PMID: 38763170 Free article.
Extended dosing of monoclonal antibodies in multiple sclerosis.
van Kempen ZL, Toorop AA, Sellebjerg F, Giovannoni G, Killestein J. van Kempen ZL, et al. Mult Scler. 2022 Nov;28(13):2001-2009. doi: 10.1177/13524585211065711. Epub 2021 Dec 24. Mult Scler. 2022. PMID: 34949134 Review.
Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis.
Rodriguez-Mogeda C, van Lierop ZYGJ, van der Pol SMA, Coenen L, Hogenboom L, Kamermans A, Rodriguez E, van Horssen J, van Kempen ZLE, Uitdehaag BMJ, Teunissen CE, Witte ME, Killestein J, de Vries HE. Rodriguez-Mogeda C, et al. Among authors: van kempen zle. J Neuroinflammation. 2023 Sep 26;20(1):215. doi: 10.1186/s12974-023-02900-z. J Neuroinflammation. 2023. PMID: 37752582 Free PMC article.
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
Verstegen NJM, Hagen RR, Kreher C, Kuijper LH, Dijssel JVD, Ashhurst T, Kummer LYL, Palomares Cabeza V, Steenhuis M, Duurland MC, Jongh R, Schoot CEV, Konijn VAL, Mul E, Kedzierska K, van Dam KPJ, Stalman EW, Boekel L, Wolbink G, Tas SW, Killestein J, Rispens T, Wieske L, Kuijpers TW, Eftimov F, van Kempen ZLE, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group. Verstegen NJM, et al. Among authors: van kempen zle. J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):855-864. doi: 10.1136/jnnp-2023-332224. J Neurol Neurosurg Psychiatry. 2024. PMID: 38548324 Free PMC article.
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical data.
Noteboom S, Strijbis EMM, Coerver EME, Colato E, van Kempen ZLE, Jasperse B, Vrenken H, Killestein J, Schoonheim MM, Steenwijk MD. Noteboom S, et al. Among authors: van kempen zle. Mult Scler Relat Disord. 2024 Jul;87:105670. doi: 10.1016/j.msard.2024.105670. Epub 2024 May 10. Mult Scler Relat Disord. 2024. PMID: 38772150 Free article.
A personalized approach for anti-CD20 therapies in multiple sclerosis.
Hogenboom L, van Kempen ZLE, Kalincik T, Bar-Or A, Killestein J. Hogenboom L, et al. Among authors: van kempen zle. Mult Scler Relat Disord. 2024 Nov;91:105851. doi: 10.1016/j.msard.2024.105851. Epub 2024 Aug 31. Mult Scler Relat Disord. 2024. PMID: 39236647 Review.
68 results